



Date: July 26, 2023

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code : INDOCO-EQ	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code : 532612
---	---

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 –Completion of Inspection at Indoco Remedies Limited Baddi Unit-I

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Competent Health Authority of Malta had inspected Company's manufacturing facility for solid oral dosage form (Unit I) located at Baddi ("Facility"), from April 20, 2023 to April 24, 2023.

The Facility has received EU GMP certification from Competent Health Authority of Malta confirming that the Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive.

Please find enclosed herewith press release in this regard. Kindly take the above information on record.

**Thanking you,
Yours faithfully,
For Indoco Remedies Limited**



**Ramanathan Hariharan
Company Secretary & Head- Legal**



PRESS RELEASE

Indoco's Baddi facility (Unit I) receives GMP certification from EU Health Authority

Mumbai, July 26, 2023: Indoco Remedies has received EU GMP certification from the Competent Health Authority of Malta for its manufacturing site in Baddi (Unit -I) located at Village Katha, Tehsil- Nalagarh, District– Solan, Himachal Pradesh.

The Agency had conducted an inspection at Indoco's manufacturing facility for solid oral dosage form from April 20 - 24, 2023.

The EU GMP certification issued by the Health Authority from Malta confirms that the site complies with the Good Manufacturing Practice requirements as referred in the EC Directive. The EU GMP certification will support supplies of drug products to Europe and other territories from this manufacturing site.

Commenting on the development, **Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd.**, said that "The EU GMP certification for our site in Baddi (Unit I), further builds upon our capability as an organization to supply quality and affordable medicines in Europe and other geographies. We are committed to remain cGMP compliant and ensure supplying quality products to our customers and patients across globe."

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries. The Company's turnover is US\$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field Staff who are the strength of the organization.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritional, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Pramod Ghorpade | Mobile: 9619883225

E-mail: pramod.ghorpade@indoco.com / corpcom@indoco.com